Kexing Pharmaceutical's GB20 Injection Gets NMPA Clinical Trial Approval for IBD
On September 21, Kexing Pharmaceutical announced its subsidiary Shenzhen Kexing received NMPA approval to begin clinical trials for GB20 Injection, a self-developed TL1A monoclonal antibody for inflammatory bowel disease (ulcerative colitis and Crohn's disease). The drug targets TNFSF15 (TL1A) to block intestinal inflammation. Preclinical studies showed improved disease activity and reduced fibrosis.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary awaiting refresh
Summary awaiting refresh
Cross-source coverage
Reporting timeline
Kexing Pharmaceutical's GB20 Injection Gets Clinical Trial Approval in China
On September 21, Kexing Pharmaceutical announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., received a 'Drug Clinical Trial Approval Notice' from China's National Medical Products Administration (NMPA). The NMPA approved the initiation of clinical trials for the company's self-developed TL1A monoclonal antibody innovative drug, 'GB20 Injection'. According to the announcement, GB20 Injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It can specifically bind to TL1A, block intestinal inflammatory cascade reactions, and reduce intestinal mucosal inflammatory damage. The drug is intended for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Read sourceKexing Pharmaceutical's self-developed TL1A monoclonal antibody GB20 injection gets clinical trial approval
Kexing Pharmaceutical (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received a Drug Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) for its self-developed TL1A monoclonal antibody innovative drug, GB20 injection. The approved indication is inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis. The article explains that the TL1A target has a dual mechanism of anti-inflammation and anti-fibrosis, as it is an upstream inflammatory regulator and activates the TGF-β/Smad pathway driving intestinal fibrosis. GB20 was developed using the company's KX-BODY antibody technology platform with AI-assisted drug design, improving affinity by 6 times. Preclinical studies published in Frontiers in Immunology showed GB20 improved disease activity index, colon morphology, and reduced intestinal fibrosis area. The company has a pipeline of differentiated drugs in autoimmune diseases, including GB19 (BDCA2 antibody) for lupus and GB24 (TL1A/LIGHT bispecific antibody) for IBD. Kexing Pharmaceutical is pursuing an innovation and internationalization strategy, with registration and sales coverage in about 70 countries and regions.
Read sourceKexing Pharmaceutical's GB20 Injection Gets Clinical Trial Approval from China's NMPA
Kexing Pharmaceutical (688136.SH) announced on September 21 that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received a Drug Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA). The NMPA approved the initiation of clinical trials for GB20 Injection, a self-developed innovative TL1A monoclonal antibody drug. GB20 Injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It specifically binds to TL1A to block intestinal inflammatory cascades and reduce intestinal mucosal inflammatory damage. The drug is intended for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Read sourceShow 3 older updatesHide older updates
Kexing Pharmaceutical's GB20 Injection Gets Clinical Trial Approval from China's Drug Regulator
On September 21, Kexing Pharmaceutical (688136.SH) announced that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received a 'Drug Clinical Trial Approval Notice' from the National Medical Products Administration (NMPA) of China. The NMPA has approved the company's self-developed TL1A monoclonal antibody innovative drug, 'GB20 Injection,' to proceed with clinical trials. GB20 Injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It works by specifically binding to TL1A, thereby blocking the intestinal inflammatory cascade and reducing intestinal mucosal inflammatory damage. The drug is intended for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease.
Read sourceKexing Pharmaceutical's GB20 Injection Gets Clinical Trial Approval in China
Kexing Pharmaceutical (688136) announced on September 21 that its wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd., has received a Drug Clinical Trial Approval Notice from China's National Medical Products Administration (NMPA). The approval allows the company to initiate clinical trials for GB20 Injection, a self-developed innovative TL1A monoclonal antibody drug. GB20 Injection is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It works by specifically binding to TL1A, blocking the intestinal inflammatory cascade, and reducing intestinal mucosal inflammatory damage. The drug is intended for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. This marks a regulatory milestone for the company's pipeline in autoimmune gastrointestinal therapies.
Read sourceKexing Pharmaceutical's GB20 Injection Gets Clinical Trial Approval for Inflammatory Bowel Disease
Kexing Pharmaceutical announced that its GB20 injection has received clinical trial approval. According to the company's announcement, GB20 is a humanized monoclonal antibody targeting tumor necrosis factor superfamily member 15 (TNFSF15, also known as TL1A). It works by specifically binding to TL1A to block the intestinal inflammatory cascade and reduce intestinal mucosal inflammatory damage. The drug is intended for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease. The information was sourced from Beijing Business Today.
Read source